Po72 Clinical Safety and Efficacy of Long-Term Use of Zoledronic Acid Hydrate for Breast Cancer Bone Metastasis
Osako, T.; Nishimura, R.; Nishiyama, Y.; Tashima, R.; Nakano, M.; Fujisue, M.; Goto, Y.; Kondo, G.
The Breast 22: S44-S45
2013
DOI: 10.1016/s0960-9776(13)70086-9
Accession: 067139170
PDF emailed within 0-6 h: $19.90
Related References
Wang, Q.; Guo, G.; Ruan, Z.; Cao, H.; Guo, Y.; Bai, L.; Jiang, C.; Liu, S.; He, W.; Huang, J.; Rong, Y.; Chen, X.; Xia, L.; Zhang, B.; Peng, R. 2020: Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China Journal of Oncology 2020: 5670601Saad, F.; Gleason, D.; Murray, R.; Venner, P.; Tchekmedyian, S.; Lacombe, L.; Chin, J.; Vinholes, J.; Goas, J.A.; Zheng, M. 2004: Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases European Urology Suppls 3(2): 156
Lipton, A.; Dewar, R.; Conte, P.; Zheng, M. 2004: Long-term safety of zoledronic acid for the treatment of patients with breast cancer and bone metastases EJC Suppls 2(3): 142
Cartenì, G.; Bordonaro, R.; Giotta, F.; Lorusso, V.; Scalone, S.; Vinaccia, V.; Rondena, R.; Amadori, D. 2006: Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial Oncologist 11(7): 841-848
Coleman, R.; Rosen, L.; Zheng, M. 2004: Zoledronic acid has long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer EJC Suppls 2(3): 127-128
Kokufu, I.; Yamamoto, M.; Noda, T.; Hiratsuka, M.; Nishikawa, H. 2016: Long-term safety and efficacy of bisphosphonate (BP) therapy for more than 24 months (M) in breast cancer (BC) patients (pts) with bone metastasis (BM) Journal of Clinical Oncology 23(16_Suppl): 816-816
Kraj, M.; Poglod, R.; Maj, S.; Pawlikowski, J.; Sokolowska, U.; Szczepanik, J. 2004: Long-term efficacy and safety of zoledronic acid compared with pamidronate in the treatment of myeloma bone disease Acta Haematologica Polonica 35(2): 227-241
Doggrell, S.A. 2009: Clinical efficacy and safety of zoledronic acid in prostate and breast cancer Expert Review of Anticancer Therapy 9(9): 1211-1218
Löthman, H.; Heatley, S.; Lipton, A. 2006: Zoledronic acid (zol) provides long-term palliation of bone pain in breast cancer (bc) patients (pts) with bone metastases European Journal of Oncology Nursing 10(3): 225-226
Rosen, L.S.; Gordon, D.; Belch, A.; Seaman, J.; Chen, B.L.an 2002: Long-Term Efficacy and Safety of 4 mg Zoledronic Acid for the Treatment of Multiple Myeloma Bone Disease A Randomized, Phase III, Comparative Trial with Pamidronate Blood 100(11): Abstract No. 5139
Facchini, G.; Caraglia, M.; Santini, D.; Nasti, G.; Ottaiano, A.; Striano, S.; Maiolino, P.; Ruberto, M.; Fiore, F.; Tonini, G.; Budillon, A.; Iaffaioli, R.V.; Zeppetella, G.L. 2007: The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE) Journal of Experimental and Clinical Cancer Research: Cr 26(3): 307-312
Dong, M.; Yi, F.F. 2016: Efficacy and safety of zoledronic acid in patients with moderate to severe pain induced by bone metastasis associated with solid tumor or multiple myeloma: A randomized, double-blind, multicenter phase III clinical trial Journal of Clinical Oncology 26(15_Suppl): 14679-14679
Mizuta, N.; Sakaguchi, K.; Mizuta, M.; Ichida, M.; Ohashi, M.; Umeda, Y.; Nishiyama, A.; Matsumoto, M.; Fujiwara, I. 2010: Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(7): 1317-1320
Kim, Y.; Kim, K.; Oh, I.; Jung, J.; Son, J.; Jang, T.; Jung, M.; Son, C.; Lee, S.; Kim, S.; Kim, E.; Lee, K.; Ryu, J. 2007: P1-254: Efficacy of Zoledronic acid in Lung cancer with bone metastasis Journal of Thoracic Oncology 2(8): S839-S840
Wei, Z.; Pan, B.; Jia, D.; Yu, Y. 2022: Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis Future Oncology 18(18): 2257-2267
Abdel Halim, I.; Elashry, M.; Elsherbini, E.; Elsadda, W. 2009: Zoledronic acid in breast cancer patients with bone metastasis European Journal of Cancer Supplements 7(2): 279-280
Wu, C.; Yang, S.; Sun, Z.; Han, X.; Ye, Y.; Liu, S. 2014: Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy Pathology Oncology Research: Por 20(3): 747-754
Søe, K.; Plesner, T.; Jakobsen, E.H.; Hansen, C.T.; Jørgensen, H.B.; Delaissé, J.-M. 2013: Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis? Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research 28(8): 1738-1750
Khalafallah, A.A.; Slancar, M.; Cosolo, W.; Abdi, E.; Chern, B.; Woodfield, R.J.; Copeman, M.C. 2018: Long-term safety of monthly zoledronic acid therapy beyond 1 year in patients with advanced cancer involving bone (LoTESS): A multicentre prospective phase 4 study European Journal of Cancer Care 27(2): E12638
Okada, Y.; Abe, T.; Nakajima, Y.; Okuda, I.; Lohman, B.D.; Kanemaki, Y.; Kojima, Y.; Tsugawa, K. 2015: Bone Scan Index Is a Prognostic Factor for Breast Cancer Patients with Bone Metastasis Being Treated with Zoledronic Acid Open Journal of Radiology 05(03): 149-158